Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
You may also be interested in...
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
The latest drug development news and highlights from our US FDA Performance Tracker.
What's next for the PD-1 market, a cancer therapy area that exploded in 2017 as recently launched products secured ever more approvals? Maria Whitman, managing principal at sales and marketing firm ZS Associates, talks about challenges facing the booming immuno-oncology market and shares her predictions for 2018.